Literature DB >> 10408453

Diplopia secondary to aniseikonia associated with macular disease.

N M Benegas1, J Egbert, W K Engel, B J Kushner.   

Abstract

OBJECTIVE: To provide an explanation for diplopia and the inability to fuse in some patients with macular disease.
METHODS: We identified 7 patients from our practices who had binocular diplopia concurrent with epiretinal membranes or vitreomacular traction. A review of the medical records of all patients was performed. In addition to complete ophthalmologic and orthoptic examinations, evaluation of aniseikonia using the Awaya New Aniseikonia Tests (Handaya Co Ltd, Tokyo, Japan) was performed on all patients.
RESULTS: All patients were referred for troublesome diplopia. Six of the patients had epiretinal membranes and 1 had vitreomacular traction. All 7 patients had aniseikonia, ranging from 5% to 18%. In 5 of the patients the image in the involved eye was larger, and in the other 2 patients it was smaller than in the fellow eye. All patients had concomitant small-angle strabismus and at least initially did not fuse when the deviation was offset with a prism. Response to optical management and retinal surgery was variable.
CONCLUSIONS: Aniseikonia caused by separation or compression of photoreceptors can be a contributing factor to the existence of diplopia and the inability to fuse in patients with macular disease. Concomitant small-angle strabismus and the inability to fuse with prisms may lead the clinician to the incorrect diagnosis of central disruption of fusion. Surgical intervention does not necessarily improve the aniseikonia.

Entities:  

Mesh:

Year:  1999        PMID: 10408453     DOI: 10.1001/archopht.117.7.896

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  12 in total

1.  Comparison of visual acuity, metamorphopsia, and aniseikonia in patients with an idiopathic epiretinal membrane.

Authors:  Atsuhiro Tanikawa; Yoshiaki Shimada; Masayuki Horiguchi
Journal:  Jpn J Ophthalmol       Date:  2018-04-06       Impact factor: 2.447

2.  Potential role of Müller cells in the pathogenesis of macropsia associated with epiretinal membrane: a hypothesis revisited.

Authors:  Ahmet Colakoglu; Solmaz Balci Akar
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

3.  Aniseikonia associated with epiretinal membranes.

Authors:  M Ugarte; T H Williamson
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

4.  Preoperative aniseikonia is a prognostic factor for postoperative stereopsis in patients with unilateral epiretinal membrane.

Authors:  Fumiki Okamoto; Shohei Morikawa; Yoshimi Sugiura; Sujin Hoshi; Takahiro Hiraoka; Tetsuro Oshika
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-02-21       Impact factor: 3.117

5.  Treatment for Central-Peripheral Rivalry-Type Diplopia ("Dragged-Fovea Diplopia Syndrome").

Authors:  Sarah R Hatt; David A Leske; Lindsay D Klaehn; Andrea M Kramer; Raymond Iezzi; Jonathan M Holmes
Journal:  Am J Ophthalmol       Date:  2019-07-16       Impact factor: 5.258

6.  Associations of aniseikonia with metamorphopsia and retinal displacements after epiretinal membrane surgery.

Authors:  Y Ichikawa; Y Imamura; M Ishida
Journal:  Eye (Lond)       Date:  2017-09-22       Impact factor: 3.775

7.  Aniseikonia in various retinal disorders.

Authors:  Fumiki Okamoto; Yoshimi Sugiura; Yoshifumi Okamoto; Takahiro Hiraoka; Tetsuro Oshika
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-01-25       Impact factor: 3.117

8.  Causes of Diplopia in Patients With Epiretinal Membranes.

Authors:  Kevin K Veverka; Sarah R Hatt; David A Leske; William L Brown; Raymond Iezzi; Jonathan M Holmes
Journal:  Am J Ophthalmol       Date:  2017-04-27       Impact factor: 5.258

9.  Evaluation of aniseikonia with an auto-stereoscopic smartphone.

Authors:  Lingzhi Zhao; Huang Wu
Journal:  Ann Transl Med       Date:  2019-11

10.  Botulinum toxin in the management of acquired motor fusion deficiency.

Authors:  Ramesh Murthy; Siddharth Kesarwani
Journal:  Indian J Ophthalmol       Date:  2009 Nov-Dec       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.